Get started
SCL SCIENCESS

SCL SCIENCE

2,790KRWD
+65+2.39%
As of today at 06:11 GMT
KRW
No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

246960 fundamentals

Key facts

Market capitalization‪92.23 B‬KRW
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−162.47KRW
Founded2010
Employees (FY)63
CEOMoon-Soo Lee
Websiteinnotherapy.com
About

SCL Science, Inc. engages in the manufacture and sale of hemostatic medical agents. The company operates through the Absorbable Hemostat and Surgical Sealant. Its products include homeostatic agents, sealants and adhesives. The company was founded by Moon-Soo Lee and Hae-Shin Lee on April 19, 2010 and is headquartered in Seoul, South Korea.

Ownership
‪‪33.97 M‬‬
Closely held shares
‪‪18.58 M‬‬ (54.71%)
Free Float shares
‪‪15.39 M‬‬ (45.29%)
Closely held shares
‪‪18.58 M‬‬ (54.71%)
Free Float shares
‪‪15.39 M‬‬ (45.29%)
Capital structure
Market cap
‪‪92.23 B‬‬
Debt
‪‪23.29 B‬‬
Cash & equivalents
‪‪10.97 B‬‬
Enterprise value
‪‪104.54 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪92.23 B‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
13.52x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
13.52x
Valuation ratios
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪7.00‬
‪14.00‬
‪21.00‬
‪28.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−98%‬
‪−86%‬
‪−74%‬
‪−62%‬
‪−50%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−2.40 B‬‬
‪‪−1.20 B‬‬
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−2.40 B‬‬
‪‪−1.20 B‬‬
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−2.40 B‬‬
‪‪−1.20 B‬‬
‪0.00‬
‪‪1.20 B‬‬
‪‪2.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Service
Hemostatic Agent
Catheter
Other
By country
Period: 2024
South Korea
United States
Hong Kong
Greece
Japan
Israel

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
‪0.00‬
‪‪7.00 B‬‬
‪‪14.00 B‬‬
‪‪21.00 B‬‬
‪‪28.00 B‬‬
Estimate
Earnings
Next:—
‪−160.00‬
‪−120.00‬
‪−80.00‬
‪−40.00‬
‪0.00‬
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
246960 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−8.00 B‬‬
‪0.00‬
‪‪8.00 B‬‬
‪‪16.00 B‬‬
‪‪24.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪9.00 B‬‬
‪‪18.00 B‬‬
‪‪27.00 B‬‬
‪‪36.00 B‬‬
Assets
Liabilities